Presentation is loading. Please wait.

Presentation is loading. Please wait.

TAE-684 effectively inhibits the growth of H3122 in vivo.

Published byJohanna Nurmi Modified over 5 years ago

Similar presentations

Presentation on theme: "TAE-684 effectively inhibits the growth of H3122 in vivo."— Presentation transcript:

1 TAE-684 effectively inhibits the growth of H3122 in vivo.
TAE-684 effectively inhibits the growth of H3122 in vivo. Xenografts on H3122 in nu/nu mice were generated as described in Materials and Methods. Erlotinib and TAE-684 treatments were administered by oral gavage and tumors were measured three times weekly. The control and erlotinib-treated mice reached a median tumor size of 2,000 mm3 by 15 d of treatment and were sacrificed. In contrast, the median tumor size of mice treated with TAE684 at either 10 or 25 mg/kg/d did not reach 2,000 mm3 even after 53 days of treatment. Jussi P. Koivunen et al. Clin Cancer Res 2008;14: ©2008 by American Association for Cancer Research

Download ppt "TAE-684 effectively inhibits the growth of H3122 in vivo."

Similar presentations

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.
NSCLC. NSCLC. A, antitumor activity of abemaciclib in 4 KRAS-mutant (NCI-H358, NCI-H2122, NCI-H441, NCI-H460) and 2 KRAS wild-type (WT; NCI-H1650, NCI-H1975)

NSCLC. NSCLC. A, antitumor activity of abemaciclib in 4 KRAS-mutant (NCI-H358, NCI-H2122, NCI-H441, NCI-H460) and 2 KRAS wild-type (WT; NCI-H1650, NCI-H1975)
Figure S3. in vivo Study of ABT-263 or SAR in the RS4;11 model in mice

Figure S3. in vivo Study of ABT-263 or SAR in the RS4;11 model in mice
Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Supplemental Figure 6 Supplemental Figure 6. Treatment with erlotinib plus TAS-115 inhibits the growth of PC-9/HGF tumors in vivo. (A, B) Nude mice bearing.

Supplemental Figure 6 Supplemental Figure 6. Treatment with erlotinib plus TAS-115 inhibits the growth of PC-9/HGF tumors in vivo. (A, B) Nude mice bearing.
MI-773 reduces the fraction of CSCs and prevents recurrence in ACC xenograft tumors. MI-773 reduces the fraction of CSCs and prevents recurrence in ACC.

MI-773 reduces the fraction of CSCs and prevents recurrence in ACC xenograft tumors. MI-773 reduces the fraction of CSCs and prevents recurrence in ACC.
Effect of MI-773 and/or cisplatin in a preclinical model of ACC

Effect of MI-773 and/or cisplatin in a preclinical model of ACC
Activity of MAC-321 (i. v. and p. o

Activity of MAC-321 (i. v. and p. o
Effect of MI-773 dosing on long-term efficacy.

Effect of MI-773 dosing on long-term efficacy.
Sildenafil suppresses polyp formation in the AOM/DSS model of colon cancer. Sildenafil suppresses polyp formation in the AOM/DSS model of colon cancer.

Sildenafil suppresses polyp formation in the AOM/DSS model of colon cancer. Sildenafil suppresses polyp formation in the AOM/DSS model of colon cancer.
IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells. IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells.

IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells. IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells.
Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination with olaparib. Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination.

Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination with olaparib. Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination.
TFAP2A knockdown inhibits tumor growth in vivo.

TFAP2A knockdown inhibits tumor growth in vivo.
In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s
Effects of AG on the colon histology score in the acute DSS colitis model. Effects of AG on the colon histology score in the acute DSS colitis model. Ten.

Effects of AG on the colon histology score in the acute DSS colitis model. Effects of AG on the colon histology score in the acute DSS colitis model. Ten.
NSG mice transplanted with human primary ALK-positive ALCL tumor grafts were administered either doxorubicin, 10 mg/kg i.v. or CEP-28122 orally, 100 mg/kg,

NSG mice transplanted with human primary ALK-positive ALCL tumor grafts were administered either doxorubicin, 10 mg/kg i.v. or CEP orally, 100 mg/kg,
The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. A, phospho-protein.

The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. A, phospho-protein.
coTCRcys-transduced T cells control tumor growth in vivo.

coTCRcys-transduced T cells control tumor growth in vivo.

Similar presentations

Ads by Google